Oxford, UK – 30th March 2020
Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer, announced today that its Chief Executive Officer, Bill Enright, will present an update on the Company’s progress at the upcoming Solebury Trout Virtual Investor Conference. The presentation will include recent encouraging Phase 2 efficacy data for Vaccitech’s prostate cancer therapeutic combined with an anti-PD-1 checkpoint inhibitor in metastatic castration resistant prostate cancer patients. The presentation will also outline ongoing COVID-19 vaccine efforts using Vaccitech’s proprietary ChAdOx1 vector.
Vaccitech is one of the few companies in the world that has data in humans demonstrating neutralizing antibodies against a coronavirus with its MERS (Middle Eastern Respiratory Syndrome) vaccine candidate.
Date of presentation: Tuesday, 31 Tuesday, 2020
Time: 10:00 am – 10:30 am ET
To access the presentation click here